Evidence map›Paper›PMID 39391766›Full record

ArticleMolecular therapy. Nucleic acids2024

Alternative splicing dysregulation across tissue and therapeutic approaches in a mouse model of myotonic dystrophy type 1.

Sawyer M Hicks, Jesus A Frias, Subodh K Mishra, Marina Scotti, Derek R Muscato, M Carmen Valero, Leanne M Adams, John D Cleary, Masayuki Nakamori, Eric Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. HSAInternational journal of molecular sciences · 2025
    Article
  4. Article
  5. Review
  6. Use of HSALab animal · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sawyer M HicksDepartment of Biological Sciences, College of Arts and Sciences, University at Albany, SUNY, Albany, NY 12222, USA.
Jesus A FriasDepartment of Biological Sciences, College of Arts and Sciences, University at Albany, SUNY, Albany, NY 12222, USA.
Subodh K MishraThe RNA Institute, College of Arts and Sciences, University at Albany, SUNY, Albany, NY 12222, USA.
Marina ScottiCenter for NeuroGenetics and Department of Molecular Genetics & Microbiology, College of Medicine, University of Florida, Gainesville, FL 32603, USA.
Derek R MuscatoCenter for NeuroGenetics and Department of Molecular Genetics & Microbiology, College of Medicine, University of Florida, Gainesville, FL 32603, USA.
M Carmen ValeroCenter for NeuroGenetics and Department of Molecular Genetics & Microbiology, College of Medicine, University of Florida, Gainesville, FL 32603, USA.
Leanne M AdamsCenter for NeuroGenetics and Department of Molecular Genetics & Microbiology, College of Medicine, University of Florida, Gainesville, FL 32603, USA.
John D ClearyThe RNA Institute, College of Arts and Sciences, University at Albany, SUNY, Albany, NY 12222, USA.
Masayuki NakamoriDepartment of Neurology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Eric WangCenter for NeuroGenetics and Department of Molecular Genetics & Microbiology, College of Medicine, University of Florida, Gainesville, FL 32603, USA.
J Andrew BerglundDepartment of Biological Sciences, College of Arts and Sciences, University at Albany, SUNY, Albany, NY 12222, USA.

Funding

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research CenterP50NS048843 · NINDS · UNIVERSITY OF ROCHESTER · PI THORNTON, CHARLES A · 2018 to 2022
$7.1M
Training CoreP50AR085906 · NIAMS · VIRGINIA COMMONWEALTH UNIVERSITY · PI Nicholas Elwood Johnson · 2025 to 2026
$4.1M
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic DystrophyR01NS120485 · NINDS · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI Andrew Berglund, Masayuki Nakamori · 2022 to 2026
$2.7M
Alternative Splicing and Development of Small Molecule Therapeutics in CAG Expansion Spinocerebellar AtaxiasR01NS135254 · NINDS · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI Andrew Berglund, Damian Seung-Ho Shin · 2024 to 2026
$2.0M
NIAMS NIH HHS P50 AR085906NINDS NIH HHS P50 NS048843NINDS NIH HHS R01 NS120485NINDS NIH HHS R01 NS135254
6 · The paper itself

Abstract

Myotonic dystrophy type 1 (DM1), the leading cause of adult-onset muscular dystrophy, is caused by a CTG repeat expansion. Expression of the repeat causes widespread alternative splicing (AS) defects and downstream pathogenesis, including significant skeletal muscle impacts. The

Indexed as

alternative splicingDM1HSALRMT: BioinformaticsRNA-seqRNA sequencingtherapeutics

Identifiers

PMID39391766
PMCPMC11465180

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.